TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05836974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex-utero cord blood collection
Description: SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-utero cord blood collection
Description: The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
Study: NCT06350695

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low grade compression stockings (10-15 mmHg)
Description: Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high grade compression stockings (20-30 mmHg)
Description: Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
Study: NCT05047731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Description: Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
Study: NCT05356364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Description: cognitive and behavioral treatment for perinatal insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Description: Mindfulness and behavioral based therapy for perinatal insomnia.
Study: NCT05044975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will receive sleep restriction intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus control
Description: Participants will receive stimulus control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus control
Description: Participants will receive stimulus control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus control
Description: Participants will receive stimulus control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus control
Description: Participants will receive stimulus control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic light exposure
Description: Participants will receive systematic light exposure intervention
Study: NCT06328400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension Placebo
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study: NCT05044975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic light exposure
Description: Participants will receive systematic light exposure intervention
Study: NCT06328400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension Placebo
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension Placebo
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study: NCT05740683

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-QuiC
Description: RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-QuiC
Description: RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
Study: NCT05644821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex intervention
Description: The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist.

Intervention type: OTHER
Group type: OTHER
Intervention: current clinical practice
Description: current clinical practice
Study: NCT06268405

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography (PEM)
Description: PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
Study: NCT05177354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inceptiv
Description: Implantable Neurostimulator with Neuro Sense
Study: NCT05960448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (TSCS)
Description: This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Spinal Cord Stimulation
Description: This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
Study: NCT06648369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAX-ICH care bundle
Description: The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
Study: NCT06648512

Intervention type: OTHER
Intervention: No Interventions
Description: No Intervention

Intervention type: OTHER
Intervention: No Interventions
Description: No Intervention
Study: NCT06647680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
Description: Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
Study: NCT05699356

Intervention type: OTHER
Intervention: Non Surgical treatment
Description: Non Surgical
Study: NCT06649539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: 4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
Study: NCT06648057

Intervention type: DRUG
Intervention: lenvatinib plus pembrolizumab
Description: * The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens).
Study: NCT06649396

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot
Description: Comparing analysis results between dried blood spot and plasma

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis on plasma
Description: Analysis on plasma
Study: NCT06648577

Intervention type: PROCEDURE
Intervention: Ultrasound imaging
Description: The participants are scanned with an ultrasound scanner
Study: NCT05273060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Nasal Reconstruction Planning
Description: 3D molds or models to use in the reconstruction of nasal cartilage
Study: NCT06105970

Intervention type: OTHER
Intervention: No intervention
Description: cross sectional study#no intervention
Study: NCT03673748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC)
Description: Endovenous injection of MSV in saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Endovenous injection of saline solution without cells
Study: NCT05966506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad-based Zoom health coaching
Description: This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 \&11) for 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit activity monitor
Description: Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic newsletters
Description: Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
Study: NCT05044975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic light exposure
Description: Participants will receive systematic light exposure intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic light exposure
Description: Participants will receive systematic light exposure intervention
Study: NCT05699356

Intervention type: OTHER
Intervention: Non Surgical treatment
Description: Non Surgical

Intervention type: OTHER
Intervention: Non Surgical treatment
Description: Non Surgical

Intervention type: PROCEDURE
Intervention: laparoscopic drilling
Description: Surgical intervension

Intervention type: BEHAVIORAL
Intervention: Treatment of Poly cystic ovary for infertility by Life style modification
Description: Non Surgical

Intervention type: PROCEDURE
Intervention: Treatment of Poly cystic ovary for infertility by Assisted reproductive technique
Description: Surgical intervention
Study: NCT04956419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8008 capsule
Description: once daily for 2 days(Day 1 and Day 2),oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole capsule
Description: once daily for 2 days(Every 72 hours) ,oral
Study: NCT05977257

Intervention type: DEVICE
Intervention: VitaFlow® Transcatheter Aortic Valve Replacement System
Description: This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
Study: NCT06241196

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Description: Implant will be placed through the surgical guide in the extraction socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant
Description: Implant will be placed through the surgical guide in the extraction socket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Socket Therapy
Description: tunnel incision will be made in labial vestibule
Study: NCT05329584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace Subacromial Tissue Spacer
Description: Rotator Cuff Tear Treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace Subacromial Tissue Spacer
Description: Rotator Cuff Tear Treatment
Study: NCT05977127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: Administration of Comirnaty vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Administration of Comirnaty vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Administration of Comirnaty vaccine
Study: NCT06241196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Socket Therapy
Description: tunnel incision will be made in labial vestibule
Study: NCT05686161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SW-BIC-213;SARS-Cov-2.
Description: The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm (BIBP);SARS-Cov-2.
Description: The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer(BNT162b2);SARS-Cov-2.
Description: The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.
Study: NCT06241196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: allogenic soft tissue substitute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenogenic bone membrane shield
Description: xenogenic bone membrane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenogenic bone membrane shield
Description: xenogenic bone membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: soft tissue harvesting from palate
Study: NCT06274580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embolization of the middle meningeal artery
Description: Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
Study: NCT06428838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: The study treatment consists of a single infusion of eptinezumab (100mg/mL).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.
Study: NCT06116214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vachellia Nelotica
Description: As a root canal irrigant (herbal)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: As a root canal irrigant
Study: NCT04824248

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognition-targeted exercise therapy
Description: Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognition-targeted exercise therapy
Description: Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight reduction program
Description: Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.